Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KX2-361 in advanced malignancies
NCT02326441Phase 1Completed
- Sponsor
- Athenex
- Start
- Dec 2014
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of kx2-361 in solid tumor (advanced stage), lymphoma and high-grade glioma (HGG), sponsored by Athenex. Primary endpoint: Maximum Tolerated Dose at 12 months. Started Dec 2014; status: completed.
02
Drugs
kx2-361
03
Conditions
solid tumor (advanced stage)lymphomahigh-grade glioma (HGG)
Beyond the preview
Go deeper on NCT02326441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02326441.